Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04796207 · ClinicalTrials.gov registry record · NA
The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes
A NA study, sponsored by University of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT04796207: Completed NA study, sponsored by University of Arizona.
NCT04796207 is a NA study that has completed, run by University of Arizona. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04796207, a NA study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
Determine if the daily docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) supplement will reduce serum levels of biomarkers of sub-concussion injuries over a course of American football season among collegiate football athletes.
Primary Outcome
This primary outcome covers the change in the plasma brain biomarker Neurofilament Light Chains (Nf-L) due to sub-concussion injury from baseline to predetermined measurement time points. Nf-L (neuron specific intermediate proteins) are released upon injury to neurons and axons. Measured in picograms per milliliter (pg/ml)
Interventions
- DIETARY_SUPPLEMENT Fish Oil (DPA+EPA 2:1 ratio) Capsules
- DIETARY_SUPPLEMENT High Oleic Safflower Oil Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-05-28 |
| Est. Completion | 2020-01-28 |
| Phase | NA |
What the finished NCT04796207 record still lists
NCT04796207 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Fish Oil (DPA+EPA 2:1 ratio) Capsules is the first listed.
NCT04796207 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04796207 about?
NCT04796207 is a clinical study titled "The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes". Determine if the daily docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) supplement will reduce serum levels of biomarkers of sub-concussion injuries over a course of American football season among collegiate football athletes.
What is the current status of trial NCT04796207?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2019-05-28. Estimated completion is 2020-01-28.
What interventions are being tested in trial NCT04796207?
The interventions under investigation include: Fish Oil (DPA+EPA 2:1 ratio) Capsules (DIETARY_SUPPLEMENT), High Oleic Safflower Oil Capsules (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04796207?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04796207's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI